These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20305561)

  • 41. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].
    Sixdorf U; Bauer H; Märker-Hermann E
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2266-9. PubMed ID: 17036267
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
    Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z
    Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The treatment of lupus nephritis.
    D'Cruz DP; Hughes GR
    BMJ; 2005 Feb; 330(7488):377-8. PubMed ID: 15718519
    [No Abstract]   [Full Text] [Related]  

  • 45. Late response to rituximab in a dialysis patient with severe lupus nephritis.
    Hussein MM; Mooij JM; Al Malki N; Demerdash TM
    Saudi J Kidney Dis Transpl; 2013 Sep; 24(5):976-80. PubMed ID: 24029264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Mycophenolate mofetil in lupus nephritis].
    Alvarez L; Rivera F; Gil CM; Jiménez del Cerro LA; Olivares J
    Nefrologia; 2002; 22(1):24-32. PubMed ID: 11987681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab treatment in lupus nephritis--where do we stand?
    Gunnarsson I; Jonsdottir T
    Lupus; 2013 Apr; 22(4):381-9. PubMed ID: 23553781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
    Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
    J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab monotherapy for remission induction of proliferative lupus nephritis flares: description of 3 cases.
    Moroni G; Gallelli B; Banfi G; Leoni A; Messa P
    J Nephrol; 2010; 23(3):357-61. PubMed ID: 20383866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.
    van Vollenhoven RF; Gunnarsson I; Welin-Henriksson E; Sundelin B; Osterborg A; Jacobson SH; Klareskog L
    Scand J Rheumatol; 2004; 33(6):423-7. PubMed ID: 15794203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
    Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
    N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mycophenolate mofetil for lupus nephritis.
    McCune WJ
    N Engl J Med; 2005 Nov; 353(21):2282-4. PubMed ID: 16306526
    [No Abstract]   [Full Text] [Related]  

  • 53. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
    Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?
    Boumpas DT; Sidiropoulos P; Bertsias G
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):22-30. PubMed ID: 16932624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapy of lupus nephritis with mycophenolate mofetil].
    Celić D; Ilić T; Durdević-Mirković T; Mitić I; Milić B; Curić S
    Med Pregl; 2007; 60 Suppl 2():124-7. PubMed ID: 18928177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of clinical deterioration in patients with lupus nephritis receiving rituximab.
    Manou-Stathopoulou S; Robson MG
    Lupus; 2016 Oct; 25(12):1299-306. PubMed ID: 27084027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis.
    Marks SD; Tullus K
    Acta Paediatr; 2010 Jul; 99(7):967-74. PubMed ID: 20222881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine.
    Fu YF; Liu GL
    Clin Nephrol; 2001 Apr; 55(4):318-21. PubMed ID: 11334319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report.
    Edelbauer M; Jungraithmayr T; Zimmerhackl LB
    Pediatr Nephrol; 2005 Jun; 20(6):811-3. PubMed ID: 15772840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction therapy with rituximab for lupus nephritis due to prolidase deficiency.
    Sato S; Ohnishi T; Uejima Y; Furuichi M; Fujinaga S; Imai K; Nakamura K; Kawano Y; Suganuma E
    Rheumatology (Oxford); 2020 Oct; 59(10):e57-e59. PubMed ID: 32107546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.